{
    "organizations": [],
    "uuid": "2101a709f654e8d9465a847a52604c4d8b90ee68",
    "author": "",
    "url": "https://www.reuters.com/article/brief-anthera-announces-positive-outcome/brief-anthera-announces-positive-outcome-of-second-interim-futility-analysis-in-the-phase-3-sollpura-study-idUSFWN1PH0UX",
    "ord_in_thread": 0,
    "title": "BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 50 PM / Updated 5 minutes ago BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study Reuters Staff 1 Min Read \nJan 22 (Reuters) - Anthera Pharmaceuticals Inc: \n* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER \n* ANTHERA PHARMACEUTICALS INC - ON TRACK TO REPORT TOPLINE DATA LATER THIS QUARTERâ€‹ FROM RESULT STUDY Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T15:48:00.000+02:00",
    "crawled": "2018-01-22T16:01:47.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "positive",
        "outcome",
        "second",
        "interim",
        "futility",
        "analysis",
        "phase",
        "sollpura",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "anthera",
        "pharmaceutical",
        "inc",
        "anthera",
        "announces",
        "positive",
        "outcome",
        "second",
        "interim",
        "futility",
        "analysis",
        "phase",
        "result",
        "clinical",
        "study",
        "sollpura",
        "study",
        "schedule",
        "topline",
        "data",
        "quarter",
        "anthera",
        "pharmaceutical",
        "inc",
        "track",
        "report",
        "topline",
        "data",
        "later",
        "result",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}